Navigation Links
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
Date:10/29/2010

nse_USA_ENG.pdf) and Medication Guide, (http://medguide.shirecontent.com/MEDGUIDE/PDFs/MG_Vyvanse_USA_ENG.pdf) including Warning about Potential for Abuse, and discuss with your doctor.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's prod
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
2. Change of Name to Shire plc
3. Shires New Product Portfolio Delivers Strong Quarterly Performance
4. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
5. Shire plc: Change to Directors Details
6. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
7. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
8. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
9. Shire Announces Opening of Office in Japan
10. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
11. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
(Date:1/14/2014)... January 14, 2014 Independent publisher Bitingduck ... and Montreal, Canada, has big ideas for 2014 in ... press's goals are to produce high-quality, low-cost, DRM-free ebooks ... local businesses. , The first major development will ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 12 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... and,nine months ended Sept. 30, 2007. Third ... for the third quarter and nine months ended ... respectively, compared with $16.5 million,and $30.2 million, respectively, ...
... Fla., Nov. 12 GeoPharma, Inc. (Nasdaq:,GORX) (the ... an,approval from the FDA to begin producing Carprofen. ... is a,non-steroidal anti-inflammatory drug (NSAID) that is used ... associated with osteoarthritis in,dogs. Additionally, Carprofen is often ...
... Toronto Stock Exchange Symbol: MS, EDMONTON, Nov. ... leading developer in the treatment of multiple sclerosis ... been enrolled in its MAESTRO-03,U.S. pivotal phase III ... progressive multiple sclerosis (SPMS). An interim safety and,efficacy ...
Cached Biology Technology:Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 6GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen 2GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen 3BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 2BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 3
(Date:4/17/2014)... the process whereby the genetic information of DNA ... proteins, which have numerous different functions in living ... intermediary during gene expression, by relating the genetic ... in manufacturing proteins. , By examining the ... in an organism at a given time, researchers ...
(Date:4/17/2014)... National University (ANU), have developed a new way ... over the past 5.3 million years., The findings ... ice ages over the past two million years, ... dioxide levels, global temperatures and sea levels., The ... and the National Oceanography Centre (NOC) in the ...
(Date:4/16/2014)... collections two new species of yellow-shouldered bats have been unearthed by ... Museum of Natural History and described in the open access journal ... genus Sturnira are part of a recent discovery of ... one still waiting to be officially announced. , Up until recently ...
Breaking Biology News(10 mins):Rapid and accurate mRNA detection in plant tissues 2Ancient sea-levels give new clues on ice ages 2Two new species of yellow-shouldered bats endemic to the Neotropics 2
... and bees may do it, but the microscopic animals called ... thank you. Whats more, they have done so over millions ... These hardy creatures somehow escape the usual drawback of asexuality ... Meselson, and their colleagues are finding out how. ...
... to permanent paralysis and loss of sensation below the site ... The nerve fibers or axons have the capacity to grow ... develops around the injury. Northwestern University researchers have ... of scar tissue at the injury site and enables the ...
... available in French . , Modern ... of the worlds water flows, with potentially sudden and ... them researchers at the Stockholm University-affiliated Stockholm Resilience Centre ... published April 1 in the journal Trends in Ecology ...
Cached Biology News:Is DNA repair a substitute for sex? 2Is DNA repair a substitute for sex? 3Promising new nanotechnology for spinal cord injury 2Sudden 'ecosystem flips' imperil world's poorest regions, say water experts 2Sudden 'ecosystem flips' imperil world's poorest regions, say water experts 3
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
interferon-related developmental regulator 2...
Biology Products: